HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

N-(1-methyl-2-phenylethyl)adenosine (S-PIA)

Subscribe to New Research on N-(1-methyl-2-phenylethyl)adenosine

RN given refers to cpd without isomeric designation; structure given in first source

Also Known As:

S-PIA; (N6)-1-phenyl-2-propyladenosine; 1-MPEAD; N(6)-(1-methyl-2-phenethyl)adenosine; N(6)-(2-phenylisopropyl)adenosine; N-(1-methyl-2-phenylethyl)adenosine, (R)-isomer; N-(1-methyl-2-phenylethyl)adenosine, (S)-isomer; N6-PPA; R-PIA

Networked: 73 relevant articles (2 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Nehlig, Astrid: 2 articles (10/2011 - 01/2011)
2.	Fernandes, Maria José da Silva: 2 articles (10/2011 - 01/2011)
3.	Rosim, Fernanda Elisa: 2 articles (10/2011 - 01/2011)
4.	Persike, Daniele Suzete: 2 articles (10/2011 - 01/2011)
5.	Rybak, Leonard P: 2 articles (01/2010 - 05/2004)
6.	Ramkumar, Vickram: 2 articles (01/2010 - 05/2004)
7.	von Heijne, M: 2 articles (01/2001 - 07/2000)
8.	Hao, J X: 2 articles (01/2001 - 07/2000)
9.	Sollevi, A: 2 articles (01/2001 - 07/2000)
10.	Xu, X J: 2 articles (01/2001 - 07/2000)

Related Diseases

1.	Ischemia 10/24/1997 - "Anaesthetized dogs were randomized to a control group subjected to 40-min occlusion of a diagonal branch of left anterior descending coronary artery (LAD) followed by 1-h reperfusion, or a preconditioned group (PC) in which the same period of sustained ischemia and reperfusion was preceded by a single cycle of IP (5-min occlusion of the same LAD branch and 10-min reperfusion), or to PIA group in which R-PIA infusion into the same branch of LAD (0.4 microg/kg per min during 5 min) was followed by 10 min of perfusion prior to sustained ischemia-reperfusion. " 06/01/1996 - "Agonist-induced receptor down-regulation was not found after perfusion with R-PIA in low-flow ischemia. " 12/07/1992 - "These results indicate that the depressive action of R-PIA during ischemia results from various effects which are not restricted to a local action on the hippocampus." 05/01/1991 - "R-PIA had no effect on cerebral metabolism before ischemia. " 12/01/1992 - "It can also be deduced that the antinociceptive effects of R-PIA after intrathecal injection are not a consequence of spinal ischemia and that disturbances in local blood flow cannot be expected to constitute a neurotoxic factor."
2.	Ocular Hypertension (Glaucoma, Suspect) 05/01/1992 - "In New Zealand White rabbits, the topical administration of 500 micrograms of the relatively selective adenosine A1 receptor agonist R(-) phenylisopropyladenosine (R-PIA) produced a biphasic response in IOP in the ipsilateral eye: an initial ocular hypertension (3.5 +/- 1.4 mm of Hg) at 0.5 hour, followed by significant reduction in IOP (5 to 8 mm of Hg) from 2 to 6 hours postadministration. " 06/01/1997 - "A single unilateral topical application of R-PIA (20-250 micrograms) or CHA (20-500 micrograms) produced ocular hypertension (maximum rise = 4.9 or 3.5 mmHg) within 30 min, followed by ocular hypotension (maximum fall = 2.1 or 3.6 mmHg) from 2-6 hr. The relatively selective adenosine A2 antagonist 3,7-dimethyl-1-propargylxanthine (DMPX, 320 micrograms) inhibited the early hypertension, without influencing the hypotension. "
3.	Mononeuropathies (Mononeuritis Multiplex) 02/28/1997 - "The aim of the present study was to investigate the intrathecal (i.t.) action of a selective A1-adenosine receptor agonist, R-phenylisopropyl adenosine (R-PIA), on tactile withdrawal thresholds in a rat model of mononeuropathy produced by sciatic chronic constriction injury (CCI). " 07/29/1996 - "The aim of the present study was to investigate the effect of intravenous or intrathecal (i.t.) administration of R-phenylisopropyladenosine (R-PIA), a selective A1 adenosine receptor agonist, on spontaneous scratching behaviour, a phenomenon presumably related to pain in a mononeuropathy model (sciatic nerve ligation) in rats. "
4.	Hyperalgesia 12/01/1998 - "The anti-allodynic effect of R-PIA was maintained for 6-7 days with twice-daily administration and was reduced thereafter, particularly with respect to cold allodynia. " 12/01/1998 - "IT R-PIA completely alleviated allodynia-like behaviors to mechanical and cold stimuli in spinally injured rats. " 02/28/1997 - "R-PIA (1-10 nmol i.t.) induced a dose-dependent suppression of the tactile allodynia without producing impairment of motor function. " 09/01/2010 - "Intrathecal application of R(-)N6-(2phenylisopropyl) adenosine (R-PIA; 10 nmol), a selective A1 receptor agonist, also inhibited SCI-induced hyperalgesia. " 08/01/2008 - "Intrathecal gabapentin and R-PIA and their combination produced a dose-dependent antagonism against mechanical allodynia without severe side effects. "
5.	Seizures (Seizure) 01/01/2011 - "In conclusion our data shows that the neuroprotective effect of R-Pia was accompanied by a compensatory metabolic input in brain areas involved with seizures generation." 10/01/2011 - "This study showed that pretreatment with R-Pia and SCH58261 reduces seizure occurrence, although only R-Pia has neuroprotective properties. " 01/01/2001 - "Adenosine A1 receptor agonist, R(-)N6-(2-phenyl-isopropyl)adenosine (R-PIA) (0.01; 0.05; 0.1 mg/kg, i.p.) prolonged the latency to HS-induced convulsions. " 08/01/1993 - "However, seizure threshold was increased in the presence of CGS 21680 after blockade of the A1 receptor with CPX, or following activation of the A1 receptor with R-PIA or NECA. " 01/01/2005 - "Aminophylline and DPCPX but not 8pSPT also reversed the protective action of A1/A2 adenosine receptor agonist, 2-chloroadenosine (2-CADO) and selective A1 adenosine receptor agonist, R-N6-phenylisopropyloadenosine (R-PIA), against 3-NPA-evoked convulsions. "

Related Drugs and Biologics

1.	Phenylisopropyladenosine
2.	Adenosine A1 Receptor
3.	Glutamic Acid (Glutamate)
4.	Adenosine
5.	Purinergic P1 Receptors (Adenosine Receptor)
6.	Morphine (MS Contin)
7.	gamma-Aminobutyric Acid (GABA)
8.	Baclofen
9.	GABA-B Receptor Agonists
10.	Hydroxyl Radical

Related Therapies and Procedures

1.	Topical Administration
2.	Ligation
3.	Tourniquets
4.	Spinal Injections
5.	Analgesia